Innovating Works

H2020

Cerrada
HORIZON-HLTH-2024-IND-06-...
HORIZON-HLTH-2024-IND-06-09: Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators
ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes:
Sólo fondo perdido 2M €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 11-04-2024.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Hace más de 9 mes(es) del cierre y aún no tenemos información sobre los proyectos financiados, no parece que se vaya a publicar esta información.
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio..
Esta ayuda financia Proyectos:

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes:

European regulators gain state-of-the-art knowledge on different NAMs that are being proposed for the assessment of the safety and efficacy of chemicals and pharmaceuticals;European regulators understand better the shortcomings of the current tools based on animal procedures for the assessment of chemicals and pharmaceuticals;European regulators collaborate on a framework on how to assess the safety of chemicals based on NAM-data and how to classify the hazardous properties based on such data;European regulators collaborate on a similar framework for assessment of safety and efficacy of pharmaceuticals based on NAM-data;Citizens benefit from the supply and use of chemicals and pharmaceuticals that have been assessed through NAMs that are better predicting potential effects in humans t... ver más

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes:

European regulators gain state-of-the-art knowledge on different NAMs that are being proposed for the assessment of the safety and efficacy of chemicals and pharmaceuticals;European regulators understand better the shortcomings of the current tools based on animal procedures for the assessment of chemicals and pharmaceuticals;European regulators collaborate on a framework on how to assess the safety of chemicals based on NAM-data and how to classify the hazardous properties based on such data;European regulators collaborate on a similar framework for assessment of safety and efficacy of pharmaceuticals based on NAM-data;Citizens benefit from the supply and use of chemicals and pharmaceuticals that have been assessed through NAMs that are better predicting potential effects in humans than the current assessment methods;Industry has an improved competitive position with the availability of harmonised and standardised NAM-based assessment tools that are faster and more flexible;European Commission and Member States regulators are responding to the societal demand to move away from animal testing.
Scope:There is increasing scientific evidence pointing to the limitations of animal testing for safety and efficacy assessment of chemicals and pharmaceuticals. Europe is also experiencing a strong societal demand to move away from animal testing. Scientific progress of the past two decades has produced a number of animal-free New Approach Methodologies (NAMs) that have the potential to be used instead of the animal models that are currently employed for such testing. However, knowledge, experience and confidence on how results from the NAM assays could be used is still lacking among regulators, which could limit the industry’s use of NAMs because of lack of legal certainty when generating safety and health data requested by EU legislation.

The proposals should focus on alternatives to the use of animals for regulatory safety and efficacy testing. Applicants should propose activities that bring together NAM developers and NAM users with European regulators responsible for the safe use of chemicals (e.g. industrial chemicals, pesticides, biocides and cosmetics) and pharmaceuticals in order to inform on NAM solutions available and to encourage the building of a framework on how these NAMs could be most effectively used in the different decision-making contexts. For NAMs applicable to chemical risk assessment, collaboration with existing initiatives such as the Partnership for the Assessment of Risks from Chemicals (PARC) and the ASPIS cluster of projects (Animal-free Safety Assessment of chemicals: Project cluster for Implementation of novel Strategies) is encouraged.

To build such a framework the proposals should address all of the following:

develop technical and regulatory readiness criteriareflect on how to provide mechanisms to support technology transfer, i.e. bringing promising NAMs to the market (including optimisation and transferability assessment)discuss how to standardise NAMs and NAM-based strategies via OECD, CEN, ISO, ICH, VICH and other international organisations, as applicableprovide technical training for Contract Research Organisations (CROs) applying NAMs for regulatory purposespromote dialogue (involving companies, regulatory bodies on EU level, including ECHA, EMA and EFSA and Member States authorities) on how to integrate and interpret data from NAMs and facilitate their uptake for safety and efficacy testing of chemicals (including pesticides) and pharmaceuticals, while addressing the lack of reliability and shortcomings of the current tools based on animal proceduresidentify obstacles in EU legislation for the regulatory use of NAMs and propose options/changes in the EU regulatory framework which address these obstacles and facilitate the uptake and use of NAMs Proposals should consider involving the JRC to take advantage of its expertise and relevant activities in bridging research and regulatory communities and facilitating uptake of NAMs for regulatory application. In that respect, the JRC is open to collaborate with any successful proposal after its approval.


ver menos

Temáticas Obligatorias del proyecto: Temática principal: This topic focuses on transitioning from animal testing to New Approach Methodologies (NAMs) for assessing chemical and pharmaceutical safety and efficacy. The goal is for European regulators to adopt NAM-based tools, improving industry competitiveness, meeting societal demands, and enhancing regulatory frameworks to support NAM adoption and implementation.

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: The expected impacts of the project include:
1. Equipping European regulators with advanced knowledge on New Approach Methodologies (NAMs) for chemicals and pharmaceutical assessments
2. Enhancing regulators' understanding of NAM-based safety evaluation and classification frameworks
3. Ensuring citizens benefit from improved chemical and pharmaceutical assessment accuracy
4. Strengthening industry competitiveness with standardized NAM tools
5. Addressing societal demands for reduced animal testing by regulators and the European Commission.
The expected impacts of the project include:
1. Equipping European regulators with advanced knowledge on New Approach Methodologies (NAMs) for chemicals and pharmaceutical assessments
2. Enhancing regulators' understanding of NAM-based safety evaluation and classification frameworks
3. Ensuring citizens benefit from improved chemical and pharmaceutical assessment accuracy
4. Strengthening industry competitiveness with standardized NAM tools
5. Addressing societal demands for reduced animal testing by regulators and the European Commission.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Subcontracting costs.
Purchase costs.
Other cost categories.
Indirect costs.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 9:. La tecnología está en su forma final y funciona bajo una amplia gama de condiciones. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations. The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
El presupuesto total de la convocatoria asciende a
Presupuesto total de la convocatoria.
Proyectos financiables en esta convocatoria.
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.
Certificado DNSH: Los proyectos presentados a esta línea deben de certificarse para demostrar que no causan perjuicio al medio ambiente. + info

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-HLTH-2024-IND-06 Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Sin info.
HORIZON-HLTH-2024-IND-06-08 Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 9 meses | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2024-IND-06-09 Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 9 meses | Próxima convocatoria prevista para el mes de